Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
542
datasets available to search
ShareScore release 0.9.0
Dataset results
542 results for “HIV prevention”
Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid - preventive therapies for people living with HIV.
<p>This is the minimal data set underlying the findings of our systematic review and metasummary:</p> <p>We uploaded the following data extracted from the studies included in our review:</p> <p>- Systematic Review protocol, also published in PROSPERO (CRD42019137778).</p> <p>- detailed description of studies included in our review.</p> <p>- barriers identified in the review (metasummary).</p> <p>- facilitators identified in the review.</p>
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to
ClinicalTrials.gov study NCT01618305. IPD Sharing: YES. Countries: 7. Publications: 1.
Development of a Tailored HIV Prevention Intervention for Young Men
ClinicalTrials.gov study NCT02842060. IPD Sharing: YES. Countries: 1. Publications: 3.
Impact of a Telenovela/Soap Opera for HIV Prevention in Latinas
ClinicalTrials.gov study NCT05929482. IPD Sharing: YES. Countries: 1. Publications: 33.
Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum
ClinicalTrials.gov study NCT03386578. IPD Sharing: YES. Countries: 4. Publications: 1.
CHALO! 2.0: A Mobile Technology Based Intervention to Accelerate HIV Testing and Linkage to Preventive Treatment.
ClinicalTrials.gov study NCT04814654. IPD Sharing: YES. Countries: 1. Publications: 1.
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
ClinicalTrials.gov study NCT02135419. IPD Sharing: YES. Countries: 2. Publications: 4.
A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention
ClinicalTrials.gov study NCT04545489. IPD Sharing: YES. Countries: 1. Publications: 2.
Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention
ClinicalTrials.gov study NCT05358366. IPD Sharing: YES. Countries: 1. Publications: 30.
Data from: Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: a model of uptake and adherence to care
<p><b>Introduction</b></p> <p>Initiating and retaining pregnant women on antiretroviral therapy (ART) to prevent mother-to-child HIV transmission (PMTCT) remains a major challenge facing African HIV programs, particularly during the critical final months prior to delivery. In 2013, South Africa implemented its "Option B" PMTCT regimen (three-drug ART throughout pregnancy and breastfeeding, regardless of maternal CD4 count) and introduced once-daily fixed-dose combinations and lifelong ART. Currently, the uptake of Option B and its possible impact on adherence to PMTCT during the critical final months of pregnancy is unclear.</p> <p><b>Materials and Methods </b></p> <p>We prospectively collected visit data from a cohort of adult, HIV-infected, pregnant women between July 2013-August 2014 to estimate three models of adherence to PMTCT during the final 16 weeks immediately preceding delivery. Adherence was defined according to possession of antiretroviral drugs, which was inferred from clinic visit records under varying assumptions in each model. We describe uptake of the PMTCT regimen, gestational age at initiation, and model possible scenarios of adherence through delivery after the implementation of Option B.</p> <p><b>Results</b></p> <p>Among 138 women enrolled (median (IQR) age 28 years (24-32), median CD4 count 378 cells/mm3), median (IQR) gestational age at initiation was 22 weeks (16-26). Estimates of adherence during the final 16 weeks of pregnancy prior to delivery ranged from 75% (52-89%) under the best case scenario assumptions to 52% (30-75%) under the worst case scenario assumptions. Estimates of the proportion of women who would achieve 80% adherence to PMTCT were <50% across all models.</p> <p><b>Conclusions</b></p> <p>Despite the switch to Option B and once-daily dosing, South African women continue to initiate PMTCT late in pregnancy, and estimations of regimen adherence, as modelled using PMTCT visit attendance data, is poor, with <50% of women reaching 80% adherence during final months of pregnancy across all models. Further guideline changes and interventions are needed to achieve vertical transmission goals.</p> <p><b>Trial Registration</b></p> <p>This study was nested within the original RapIT randomized controlled trial which was registered on ClinicalTrials.gov (Registration number) NCT01710397 on September 7, 2012 and the South African National Clinical Trials Register DOH-27-0213-4177. The first participant in the RapIT study was enrolled on May 8th, 2013.</p>
Isoniazid Preventive Therapy (IPT) uptake and Tuberculin Skin Test (TST) uptake among adults receiving primary HIV care in South Africa .
<p>We aimed to evaluate Isoniazid Preventive Therapy (IPT) and tuberculin skin testing (TST) uptake under primary care clinic conditions, and determine health care worker (HCW) fidelity to the 2014 South African IPT guidelines. Following training on IPT guidelines and tuberculin skin testing (TST), 3 primary care clinics identified their IPT implementation strategy in a participatory manner. Using routine register data, TST uptake was determined 3 months before and 5 months after the intervention. Records were reviewed to identify IPT/TST uptake and factors associated with IPT initiation among adults living with HIV.</p>
Accompanying data set for the manuscript "REverSe TRanscrIptase Chain Termination (RESTRICT) for Selective Measurement of Nucleotide Analogs Used in HIV Care and Prevention"
<p>This data set contains all experimental and theoretical data included in the manuscript " REverSe TRanscrIptase Chain Termination (RESTRICT) for Selective Measurement of Nucleotide Analogs Used in HIV Care and Prevention", namely:</p> <p>RESTRICT_model: MATLAB script for completing calculations in the RESTRICT theoretical model.</p> <p>Figure 2:</p> <ul> <li>Raw data from theoretical model showing contributions of individual model components, Kaff = 0.3</li> <li>Normalized data from theoretical model showing contributions of individual model components, Kaff = 0.3</li> <li>Experimental NRTI Drug Screen 180 nt TTCA 500 nM dNTP</li> </ul> <p>Figure 3:</p> <ul> <li>Experiment-dNTP-Concentration-Screen</li> <li>Theory-dNTP-Concentration-Screen</li> <li>Experiment-Template-Length-Screen</li> <li>Theory-Template-Length-Screen</li> <li>Experiment-Sequence-Screen</li> <li>Theory-Sequence-Screen</li> </ul> <p>Figure 4:</p> <ul> <li>Experimental-NRTI-Drug-Screen-90nt-TCAA-only</li> <li>Theory-TCAA90-Kaff=0point2</li> <li>Experimental-NRTI-Drug-Screen-GGCA-only</li> <li>Theory-GGCA180-Kaff=0point2</li> </ul> <p>Figure 5:</p> <ul> <li>GGCA-vs-TTCA-Specificity-Analysis</li> </ul>
Come As You Are - Assessing the Efficacy of a Nurse Case Management HIV Prevention and Care Intervention Among Homeless Youth
ClinicalTrials.gov study NCT03910218. IPD Sharing: NO. Countries: 1. Publications: 2.
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
ClinicalTrials.gov study NCT03221309. IPD Sharing: NO. Countries: 1. Publications: 1.
Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy
ClinicalTrials.gov study NCT00099632. IPD Sharing: Not stated. Countries: 6. Publications: 6.
Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
ClinicalTrials.gov study NCT04661813. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-ge
ClinicalTrials.gov study NCT03964415. IPD Sharing: YES. Countries: 9. Publications: 1.
HIV Prevention Toolkit for HIV-negative Male Couples
ClinicalTrials.gov study NCT02494817. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Leveraging Infant Visit PrEP INtegration & tasK Shifting to Improve Post-partum HIV Prevention in Malawi
ClinicalTrials.gov study NCT06506188. IPD Sharing: YES. Countries: 1. Publications: 1.
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
ClinicalTrials.gov study NCT03643705. IPD Sharing: YES. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.